Characteristics and predictors of post-transplant-associated hemophagocytic lymphohistiocytosis in adults.
Norimichi HattoriMisuzu SatoYuka UesugiAyaka NakataYohei SasakiShotaro ShimadaMegumi WatanukiShun FujiwaraYukiko KawaguchiNana AraiYui UtoTomoharu MatsuiKouji YanagisawaSachiko TaharaH Phillip KoefflerKeiichi IezumiTsuyoshi NakamakiPublished in: International journal of hematology (2021)
Hemophagocytic lymphohistiocytosis (HLH) is an uncontrolled hyperinflammatory disorder driven by an overactive immune system that results in high mortality. Post-transplant-associated hemophagocytic lymphohistiocytosis (PT-HLH) is a type of secondary HLH that occurs following allogeneic hematopoietic stem cell transplantation (allo-HSCT). The clinical features of PT-HLH remain unclear and diagnostic and prognostic tools have not yet been established. Here, we retrospectively evaluated the clinical manifestations and outcomes of PT-HLH in 94 patients who underwent allo-HSCT. According to our PT-HLH criteria (hyperferritinemia and increased macrophage count in bone marrow), PT-HLH occurred in 12 patients (12.8%). The PT-HLH patients showed splenomegaly (P = .001), a higher risk of engraftment failure (P = .013), and an increased percentage of macrophages and hemophagocytes in bone marrow aspirates (P = .0009 and P = .0006, respectively). Moreover, univariate and multivariate analyses revealed that the survival rate was lower in PT-HLH patients than non-PT-HLH patients (P = .0017 and P = .034, respectively). This study defines the clinical features of PT-HLH and PT-HLH criteria that could be useful tools for diagnosing PT-HLH.
Keyphrases
- end stage renal disease
- bone marrow
- chronic kidney disease
- ejection fraction
- newly diagnosed
- prognostic factors
- type diabetes
- metabolic syndrome
- mesenchymal stem cells
- allogeneic hematopoietic stem cell transplantation
- patient reported outcomes
- acute myeloid leukemia
- skeletal muscle
- risk factors
- insulin resistance
- weight loss
- cord blood